• ~1hr interviews were conducted by experienced interviewers using an interview guide (topics: participants' OPRA historical activity, current perception, and future outlook) − A targeted literature review of publicly available information on specific OPRAs
• University of Washington's Performance-Based Risk Sharing (PBRS) database was accessed to extract information on OPRAs in the US and EU-5 [5] • PBRS was complemented with available information in the public domain, including: payer and health technology assessment agencies' websites, Factiva, PubMed, and congress abstracts ¢ We leveraged/adapted the OPRA taxonomy introduced by Carlson et al. (2010) [6] − An OPRA was defined for this research as "a scheme between a healthcare payer and a drug manufacturer in which the price, level or nature of reimbursement, or payer coverage of a drug are tied to one or more future clinical or other patient health measures" − Relevant outcomes were assumed to include clinical and intermediate endpoints (e.g. HbA1C, LDL), as well as financial/utilization endpoints [7] 
RESULTS

Targeted literature review results
¢ OPRA activity has steadily increased since the first arrangements twenty years ago − Europe has markedly led historical OPRA activity, with Italy implementing more than two thirds of publicly disclosed OPRAs − In the US, the literature review identified only 11 OPRA drug schemes from 1994 to 2014 (only 3 OPRA drug schemes in the past 5 years)
− Over 60 percent of the OPRAs have been in oncology, with the remaining activity in neurology, ophthalmology, endocrinology, and other therapeutic areas
Primary research results
Historical OPRA activity
¢ A significant level of OPRA activity appears to have occurred in the past 5 years (see Table 1 • Limited OPRA activity to date as manufacturers mostly motivated by "getting their feet wet" • Significant growth expected by some in order to partake in new business models (e.g. ACOs)
EU-5 ~13 (3 -30 range)~2 0 (7 -25 range)
• National focus of OPRAs appears to be primarily on new products/indications while "subnational" level focus on mature high-budget items; Local/regional contracting appears to be limited for most manufacturers • Expected increase in OPRA activity driven by new country OPRA framework introduction (e.g. Spain) and increasing budget pressures High level of OPRA activity driven by Italy
Future OPRA activity and outlook ¢ Over the next 5 years, OPRA activity is expected to increase substantially, with significant differences across countries (see Table 1) − High levels of future OPRA activity are expected in Spain, Germany, and potentially the UK (if an OPRA framework is implemented)
− Although not to the levels anticipated in Europe, US stakeholders expected significant growth in OPRA activity over the next 5 years
• ACOs were seen as a significant potential source of OPRA activity growth
• CMS was not expected to pursue any OPRA activity in the next 5 years ¢ In EU-5, future OPRA activity is expected to continue to focus on new drugs or new indications, niche, and high cost drugs:
− The exception is German (regional) sickfunds, which are expected to continue implementing OPRAs for mature, high budget items − As OPRA learning grows in the US, more OPRAs are expected to concentrate on new drugs (vs. more mature drugs historically) as well as on high-budget products
DISCUSSION
¢ OPRAs appear to be increasingly used to address certain products/situations − OPRAs are not appropriate for every product given various considerations including costs, complexity, or availability of resources − OPRAs were seen as particularly valuable for products/situations with high cost (per patient and/or budget) and unproven real-world drug value, and to achieve/demonstrate alignment with payer objectives − The increasing availability of large, integrated data sources and means to collect real world data from patients is expected to support the trend towards more OPRAs ¢ The level of OPRA success hinges on the development of pragmatic implementation frameworks − This has been demonstrated by the few established OPRA frameworks in Europe (e.g. Italy), and "trial and error" approach of certain past OPRAs (e.g. Velcade scheme in the UK) − The absence of such a framework in the US is a significant perceived barrier to OPRA activity
• The development for such OPRA frameworks in the US is challenging given the fragmented/ evolving payer and manufacturer landscapes
• Large managed care organization(s) and/or manufacturer(s) may lead development by initiating framework discussion and development, and leveraging relevant learnings from Europe [4] − Development of pragmatic implementation frameworks will be key to lower barriers to OPRAs, and increase their perceived incremental value relative to traditional pricing/reimbursement arrangements ¢ Stakeholders reported significant barriers to OPRA implementation, including limited data infrastructure, internal organizational cost, negotiation complexity, inability to align on objectives, and lack of significant perceived incremental value of OPRAs relative to traditional pricing/reimbursement arrangements for many drugs
¢ OPRA focus appears to be driven by national vs. sub-national payer types − At the national level in the EU-5, the focus of OPRAs appears to have been primarily on new or new indication, high cost (per patient) products − Sub-national focus (including Germany sickfunds and US regional managed care organizations) was generally more high-budget, mature items − Conditioning outcomes for the OPRAs were primarily therapy response-based but other outcomes (e.g. medication adherence, resource, and financial utilization) were also mentioned ¢ OPRA motivation -Payers primarily used OPRAs to reduce uncertainty about product outcomes, while manufacturers focused on product value proposition and coverage access gains − Payers and manufacturers also pursued OPRAs to gain experience with novel contracting approaches/healthcare models (e.g. ACOs in the US) − Other motivations for manufacturers included fostering better partnerships with payers, preserving price across markets, fitting into a particular payer's framework, moving discussion on value (vs. cost), and as a backup strategy ¢ OPRA hurdles -OPRAs were often constrained by the lack of an effective OPRA framework and data-related considerations − None of the manufacturers interviewed appear to have an established OPRA framework (where the same contract approach is used across payers/products) − Availability of unambiguous, mutually acceptable conditioning outcomes, and adequate source of patient data were reported as crucial for OPRA success − Aligning data expectations between OPRA partners early in the implementation stage was an important learning among research participants ¢ Interviewed stakeholders reported significantly varied experiences concerning the process used when implementing OPRAs − OPRAs typically involved several functions (e.g. pharmacy, medical, IT, legal). Early and sustained involvement of HEOR was noted as key to success by several manufacturers and payers ¢ OPRA value for payers was perceived by all stakeholders to be driven largely by economic considerations (e.g. reducing costs, risks), whereas OPRA value was reported to be driven by potential access gains for manufacturers − OPRA value was generally perceived to be in line with the historical motivation reported by interviewed stakeholders -Many US payer and manufacturer management executives appear interested in OPRAs to show-case value to customers (e.g. employers and payers, respectively), while pharmaceutical contracting staff were more reserved given feasibility of implementation Percentage of responders to note barriers as major, moderate, or not a barrier
